Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Hematology Frontier

Home » Hematology Frontier » Page 35
AZD0486 (Suvatomib) Shows Strong Efficacy and Safety in Relapsed/Refractory DLBCL丨Professor Maruyama on Latest Clinical Insights

AZD0486 (Suvatomib) Shows Strong Efficacy and Safety in Relapsed/Refractory DLBCL丨Professor Maruyama on Latest Clinical Insights

Posted by By Peng Geng 2025.09.04
Editor's Note: The global oncology community continues to focus on cutting-edge breakthroughs in lymphoma treatment. At an important academic conference, Professor Maruyama from Keio University Hospital in Tokyo, Japan, presented…
Read More
CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948

CLL Breakthrough: BTK Degrader Bexobrutideg Shows Rapid, Durable Responses丨Professor Alexey Danilov on NX-5948

Posted by By Mourabit Halima 2025.09.04
Editor's Note: At this conference, Professor Alexey Danilov (Professor of Hematology, Associate Director of the Lymphoma Center, and Director of the Early Therapeutics Program at City of Hope National Medical…
Read More
EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

Posted by By Peter W. PENG 2025.09.04
Editor's Note: At ICML conference, Professor Jose C. Villa Boas from Rochester, USA, was invited to present an oral report titled "EO2463 Peptide Immunotherapy in Combination with Lenalidomide and Rituximab…
Read More
New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

Posted by By Mourabit Halima 2025.09.04
Editor's Note: The conference brought together top experts in lymphoma research from home and abroad, engaging in in-depth discussions on cutting-edge topics such as novel molecular targeted therapies and cell…
Read More
Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

Posted by By Mourabit Halima 2025.09.03
Editor's Note: The 18th International Conference on Malignant Lymphoma (ICML) was held, gathering top experts in the lymphoma field in Lugano. At the prestigious John Ultmann Memorial Lecture, Professor Emanuele…
Read More
A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

Posted by By Ren Jiamo 2025.09.03
Editor's Note: In 2025, the International Conference on Malignant Lymphoma (ICML) convened in Switzerland, bringing together the world's leading experts in the field of lymphoma. At the conference, Professor David…
Read More
The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

Posted by By Peng Longmei 2025.09.03
Editor's Note: The International Hematologic Oncology Pathology Conference brought together top experts in hematopathology research from home and abroad for in-depth discussions on cutting-edge topics such as lymphoma diagnosis, classification…
Read More

Professor Bruce D. Cheson on Breakthroughs in Lymphoma Treatment: Innovation Pathways and Future Vision丨EHA 2025

Posted by By Mourabit Halima 2025.09.03
Editor's Note: The conference focused on the latest diagnostic and therapeutic advances in lymphoid system tumors, providing a cutting-edge academic exchange platform for the global oncology community. At this prestigious…
Read More
Professor Yuzhu Shi: The Comprehensive Value of Abdominal CT in Managing Post-Transplant Complications丨13th Lu Daopei Hematology Conference

Professor Yuzhu Shi: The Comprehensive Value of Abdominal CT in Managing Post-Transplant Complications丨13th Lu Daopei Hematology Conference

Posted by By Peter W. PENG 2025.09.03
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
Read More
Professor Hui Wang: Advancing MRD Detection in AML—From Standardization and Automation Toward Personalized Treatment

Professor Hui Wang: Advancing MRD Detection in AML—From Standardization and Automation Toward Personalized Treatment

Posted by By Mourabit Halima 2025.09.03
On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…
Read More

Posts pagination

Previous page 1 … 20
Recent Posts
  • EHA 2026 Highlight: Prof. Lars Bullinger Deciphers 25 Years of Molecular Hematology Evolution—From Gene Expression Profiles to Precision Diagnosis and Treatment Profiles
  • Second-generation vs. First-generation FLT3 Inhibitors: PASHA Study Reveals Clinical Benefits and Challenges of Gilteritinib Combined with First-line Intensive Chemotherapy
  • 83% EFS Reaches New High! AIEOP-BFM Study Confirms Replacing Chemotherapy with Blinatumomab Significantly Improves Prognosis in High-Risk B-ALL Pediatric Patients
  • As of the data analysis date, a total of 17 patients were enrolled. The median age was 63 years, the median number of prior treatment lines was 4, and 65% of patients had received at least one prior allogeneic hematopoietic stem cell transplant.
  • Precision Subtyping and BTKi Upfront: Professor Mats Jerkeman Details MCL Guideline Updates and Clinical Pathway Optimization
Recent Comments
    Archives
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top